Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.

More search options...

Sulzgruber, P; Wassmann, S; Semb, AG; Doehner, W; Widimsky, P; Gremmel, T; Kaski, JC; Savarese, G; Rosano, GMC; Borghi, C; et al. Sulzgruber, P; Wassmann, S; Semb, AG; Doehner, W; Widimsky, P; Gremmel, T; Kaski, JC; Savarese, G; Rosano, GMC; Borghi, C; Kjeldsen, K; Torp-Pedersen, C; Schmidt, TA; Lewis, BS; Drexel, H; Tamargo, J; Atar, D; Agewall, S; Niessner, A (2019) Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. Eur Heart J Cardiovasc Pharmacother, 5 (3). pp. 171-180. ISSN 2055-6845 https://doi.org/10.1093/ehjcvp/pvz016
SGUL Authors: Kaski, Juan Carlos

Preview

PDF Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (1MB) | Preview

Official URL: https://doi.org/10.1093/ehjcvp/pvz016

Abstract

Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.

Item Type:

Article

Additional Information:

This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal - Cardiovascular Pharmacotherapy following peer review. The version of record Patrick Sulzgruber, Sven Wassmann, Anne Grete Semb, Wolfram Doehner, Petr Widimsky, Thomas Gremmel, Juan Carlos Kaski, Gianluigi Savarese, Giuseppe M C Rosano, Claudio Borghi, Keld Kjeldsen, Christian Torp-Pedersen, Thomas Andersen Schmidt, Basil S Lewis, Heinz Drexel, Juan Tamargo, Dan Atar, Stefan Agewall, Alexander Niessner, Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 5, Issue 3, July 2019, Pages 171–180 is available online at: https://doi.org/10.1093/ehjcvp/pvz016 Correction available at https://doi.org/10.1093/ehjcvp/pvaa081

Keywords:

CHA2DS2-VASc score, anticoagulation, atrial fibrillation, intermediate risk

SGUL Research Institute / Research Centre:

Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)

Journal or Publication Title:

Eur Heart J Cardiovasc Pharmacother

ISSN:

2055-6845

Language:

eng

Dates: